�The pharmacological profile of SGLT2 inhibitors: Focus on mechanistic aspects and pharmacogenomics�
| dc.contributor.author | Kaur, Prabhsimran | |
| dc.contributor.author | Behera, Bidwan Sekhar | |
| dc.contributor.author | Singh, Sandeep | |
| dc.contributor.author | Munshi, Anjana | |
| dc.date.accessioned | 2024-01-21T10:54:00Z | |
| dc.date.accessioned | 2024-08-14T07:40:46Z | |
| dc.date.available | 2024-01-21T10:54:00Z | |
| dc.date.available | 2024-08-14T07:40:46Z | |
| dc.date.issued | 2021-05-11T00:00:00 | |
| dc.description.abstract | Diabetes, characterized by high glucose levels, has been listed to be one of the world's major causes of death. Around 1.6 million deaths are attributed to this disease each year. Persistent hyperglycemic conditions in diabetic patients affect various organs of the body leading to diabetic complications and worsen the disease condition. Current treatment strategies for diabetes include biguanides, sulfonylureas, alpha-glucosidase inhibitors, thiazolidinediones, insulin and its analogs, DPP-4(dipeptidyl peptidase-4) and GLP-1 (glucagon-like peptide) analogs. However, many side effects contributing to the devastation of the disease are associated with them. Sodium glucose co-transporter-2 (SGLT2) inhibition has been reported to be new insulin-independent approach to diabetes therapy. It blocks glucose uptake in the kidneys by inhibiting SGLT2 transporters, thereby promoting glycosuria. Dapagliflozin, empagliflozin and canagliflozin are the most widely used SGLT2 inhibitors. They are effective in controlling blood glucose and HbA1c levels with few side effects including hypoglycemia or weight gain which makes them preferable to other anti-diabetic drugs. However, treatment is found to be associated with inter-individual drug response to SGLT2 inhibitors and adverse drug reactions which are also affected by genetic variations. There have been very few pharmacogenetics trials of these drugs. This review discusses the various SGLT2 inhibitors, their pharmacokinetics, pharmacodynamics and genetic variation influencing the inter-individual drug response. � 2021 Elsevier B.V. | en_US |
| dc.identifier.doi | 10.1016/j.ejphar.2021.174169 | |
| dc.identifier.issn | 142999 | |
| dc.identifier.uri | http://10.2.3.109/handle/32116/4182 | |
| dc.identifier.url | https://linkinghub.elsevier.com/retrieve/pii/S0014299921003228 | |
| dc.language.iso | en_US | en_US |
| dc.publisher | Elsevier B.V. | en_US |
| dc.subject | Gliflozins | en_US |
| dc.subject | Pharmacodynamics | en_US |
| dc.subject | Pharmacogenetics | en_US |
| dc.subject | Pharmacokinetics | en_US |
| dc.subject | SGLT2 inhibitors | en_US |
| dc.title | �The pharmacological profile of SGLT2 inhibitors: Focus on mechanistic aspects and pharmacogenomics� | en_US |
| dc.title.journal | European Journal of Pharmacology | en_US |
| dc.type | Review | en_US |
| dc.type.accesstype | Closed Access | en_US |